Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 2.67% and free cash flow grew 60.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) EV/Sales
As of 16 October 2026, Rhythm Pharmaceuticals, Inc. (RYTM) trades at a EV/Sales of 23.3×. Over the past ten years it has ranged from −18.2× (May 2022) to 99.0× (March 2022); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 34.6× | 45.55% |
| FY2024 | 23.8× | (20.88%) |
| FY2023 | 30.1× | (38.73%) |
| FY2022 | 49.1× | (22.71%) |
| FY2021 | 63.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 30.4× | 18.36% |
| Mar 2026 | 25.7× | (25.87%) |
| Dec 2025 | 34.6× | (3.86%) |
| Sep 2025 | 36.0× | 50.70% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KOD Kodiak Sciences Inc. compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| IOVA Iovance Biotherapeutics, Inc. compare | 17.9× |
| LGND Ligand Pharmaceuticals Incorporated compare | 19.8× |
| RYTM Rhythm Pharmaceuticals, Inc. | 23.3× |
| CGON CG Oncology, Inc. compare | 684× |
| PRAX Praxis Precision Medicines, Inc. compare | 735× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)